Latest News and Press Releases

Presentation will showcase the novel mechanisms of degradation of Amphista's Targeted Glues™, which recruit diverse E3 ligases, including DCAF16 and FBXO22, expanding the diversity and opportunity...

The publication reports the highly selective, DCAF16 E3 enabled degradation of BRD9 in vivo using Amphista’s proprietary, next generation Targeted Glue™ medicinal chemistry technologyAmphista’s...

Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista’s clinical development capabilities and accelerate its...

AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs. The...

Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action...

Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite selectivity over close homolog, SMARCA4.Rapid, deep and...

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or...

Innovative Eclipsys® platform enables rational design of novel Targeted Glues™ with superior drug-like properties  Cambridge, UK, 22 May 2025 – Amphista Therapeutics, a leader in the discovery of...

Amphista Therapeutics to present novel mechanism of action for the degradation of BRD9 using its proprietary Targeted Glue® technology at two key upcoming scientific conferences Oral presentations...

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer Appointment supports the Company’s ambitions to advance its portfolio of next generation Targeted Glue™ protein degrader...